Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters

被引:18
作者
Bandara, Sachini [1 ,2 ]
Kennedy-Hendricks, Alene [2 ,3 ]
Merritt, Sydney [3 ]
Barry, Colleen L. [1 ,2 ,3 ]
Saloner, Brendan [1 ,2 ,3 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, 624 North Broadway Ave, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Mental Hlth & Addict Policy, Baltimore, MD 21205 USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA
关键词
Opioid agonist treatment; jail; prison; carceral settings; United States; opioids; OPIOID SUBSTITUTION THERAPY; DEATHS SOON; IMPLEMENTATION; MORTALITY; RELEASE; INCARCERATION; FACILITATORS; BARRIERS; HEALTH; IMPACT;
D O I
10.1111/add.15565
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims To identify implementation barriers and facilitators to the adoption and implementation of programs that provide opioid agonist treatments (OAT) with methadone and buprenorphine to treat opioid use disorder in jails and prisons in the United States. Design Qualitative analysis: semi-structured interviews were conducted and thematic analyses of transcripts and notes were performed using a hybrid inductive/deductive coding approach. Setting Jails and prisons in the United States. Participants From August 2019 to January 2020, we conducted 20 key informant interviews with 35 individuals representing 19 carceral systems that both initiate and maintain OAT. Measurements Interviews covered four domains: (1) program adoption; (2) policy influence on implementation; (3) program structure; and (4) program outcomes. Findings Stigma among staff, particularly medical staff, challenged program adoption, but reduced over time as staff were exposed to the program. Regulations on OAT dispensation, such as licensing requirements and prescribing limits, were key challenges to program implementation and shaped program structure. Dispensing medication required significant staff, time and space. Facilities were further challenged to overcome stigma and concerns about diversion, as OAT medication is often treated as contraband in carceral settings. Some systems deviated from evidence-based treatment by limiting OAT dosage to low levels, requiring counseling for participation and requiring detoxification before medication initiation. Despite these challenges, early adopters felt strongly that other jails and prisons in the United States should provide OAT and that legislation and litigation may soon force OAT expansion in these carceral settings. Conclusions Despite identifying regulatory and logistical challenges, early adopters of opioid agonist treatment (OAT) programs in US jails and prisons demonstrate that OAT programs can successfully be implemented in carceral settings with tailoring to the specific context.
引用
收藏
页码:3473 / 3481
页数:9
相关论文
共 35 条
  • [1] [Anonymous], 2003, Diffusion of Innovations
  • [2] [Anonymous], 2009, Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence
  • [3] Reduction in mortality risk with opioid agonist therapy: a systematic review and meta-analysis
    Bahji, A.
    Cheng, B.
    Gray, S.
    Stuart, H.
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2019, 140 (04) : 313 - 339
  • [4] Early Effects of COVID-19 on Programs Providing Medications for Opioid Use Disorder in Jails and Prisons
    Bandara, Sachini
    Kennedy-Hendricks, Alene
    Merritt, Sydney
    Barry, Colleen L.
    Saloner, Brendan
    [J]. JOURNAL OF ADDICTION MEDICINE, 2020, 14 (05) : E257 - E260
  • [5] Mortality After Prison Release: Opioid Overdose and Other Causes of Death, Risk Factors, and Time Trends From 1999 to 2009
    Binswanger, Ingrid A.
    Blatchford, Patrick J.
    Mueller, Shane R.
    Stern, Marc F.
    [J]. ANNALS OF INTERNAL MEDICINE, 2013, 159 (09) : 592 - 600
  • [6] Impact of opioid substitution therapy for Scotland's prisoners on drug-related deaths soon after prisoner release
    Bird, Sheila M.
    Fischbacher, Colin M.
    Graham, Lesley
    Fraser, Andrew
    [J]. ADDICTION, 2015, 110 (10) : 1617 - 1624
  • [7] The benefits and implementation challenges of the first state-wide comprehensive medication for addictions program in a unified jail and prison setting
    Brinkley-Rubinstein, Lauren
    Peterson, Meghan
    Clarke, Jennifer
    Macmadu, Alexandra
    Truong, Ashley
    Pognon, Kimberly
    Parker, Morgan
    Marshall, Brandon D. L.
    Green, Traci
    Martin, Rosemarie
    Stein, Lynda
    Rich, Josiah D.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2019, 205
  • [8] Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science
    Damschroder, Laura J.
    Aron, David C.
    Keith, Rosalind E.
    Kirsh, Susan R.
    Alexander, Jeffery A.
    Lowery, Julie C.
    [J]. IMPLEMENTATION SCIENCE, 2009, 4
  • [9] Diffusion Of Innovations Theory, Principles, And Practice
    Dearing, James W.
    Cox, Jeffrey G.
    [J]. HEALTH AFFAIRS, 2018, 37 (02) : 183 - 190
  • [10] The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study
    Degenhardt, Louisa
    Larney, Sarah
    Kimber, Jo
    Gisev, Natasa
    Farrell, Michael
    Dobbins, Timothy
    Weatherburn, Don J.
    Gibson, Amy
    Mattick, Richard
    Butler, Tony
    Burns, Lucy
    [J]. ADDICTION, 2014, 109 (08) : 1306 - 1317